Visible Genomics launches in-office genetic test for AMD
Visible Genomics announced the launch of a saliva-based test for age-related macular degeneration that integrates genetic information with clinical, demographic and lifestyle characteristics to assess risk.
The company stated in a press release that the genetic assessment combines the test and exam results to, “deliver a comprehensive and clinically actionable risk assessment. This assessment determines the AMD patient’s progression risk of developing advanced AMD and predicts the lifetime risk for those with a family member with AMD.”
“Our health care system is reactive instead of proactive and preventive. With use of the Visible Genomics testing system, we can now give doctors and their patients the right tools to help prevent vision loss,” Frank Adamo, Visible Genomics founder and CEO, said in the release.
The company also said in the release that the test is clinically validated and noninvasive.
“The results provided, with earlier intervention, lead to a better prognosis and outcome,” Barry Eiden, OD, FAAO, North Suburban Vision Consultants president and medical director, said in the release. “We’re now able to create a personalized patient management plan and take the proper steps by delaying disease onset or slowing disease progression.”